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FOREWORD 
The Joint Research Centre (JRC) in collaboration with the Italian National Research Council 
(CNR) organized a workshop on Technology Transfer in Nanotechnology, which took place 
in CNR Nanotec on 18th and 19th October 2018 in Lecce (Italy). This workshop was organized in the 
framework of the TTO-CIRCLE initiatives. 
The aim of this event was to explore how technology transfer activities can be used as a mechanism 
to help EU industry, particularly Start-ups and SMEs, in deploying and adopting Nano-technology. 
Practical examples were presented to illustrate the potential of technology transfer in this area. 
The workshop gathered technology providers, industry executives, technology transfer officers, 
policy makers and financial intermediaries to share experiences and lessons learned. One of the key 
objectives was to discuss policy implications at all levels that could help accelerating the adoption of 
Nanotechnology by the European manufacturing industry. 
About 120 participants attended this event. Representatives from JRC, DG RTD, European Investment 
Bank, Italian ministries, large industries, start-ups, technology transfer offices, and academics 
participated to this event.  
Authors:  
Jacqueline E M Allan1, rapporteur  
Edited by Annarita Ferreri2, Sergio Grande3, Roberto Giannantonio4 and Francesco Matteucci5
1 Joint Institute for Innovation Policy, Brussels  
2  European Commission, Joint Research Centre 
3  European Commission, Joint Research Centre 
4  DHITECH S.c.a.r.l 
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EXECUTIVE SUMMARY 
Technology transfer is an essential part of the value chain that brings research closer to the 
marketplace. The technology transfer ecosystem is broad, involving researchers, entrepreneurs, 
industries, technology transfer specialists, investors and others.  
For most academic researchers, technology transfer is largely the step of translating their research 
into a patent, or founding a company or seeking to establish a collaboration with industry. For RTOs 
(research and technology organisations), it is generally further along the value chain towards the 
market-place and involves patents, licensing and return-on-investment (in order to fund the ongoing 
activities of the RTO). For SMEs, it is often about finding the means to use their intellectual property 
to build their company towards profitability. For larger companies, including multinational 
enterprises (MNEs), technology transfer can take the form of collaborative projects, but more often it 
is about acquisitions and using patented or licensed knowledge. It  is essential that all stages and 
types of technology transfer are optimised so that Europe can capitalise fully on its economically -
relevant knowledge generation.  
Nanotechnology research, development and innovation (RDI) is part of a wider European knowl edge 
capital but there are specific characteristics that make technology transfer in nanotechnology 
(hereafter “nanotechnology transfer”) more complex and demanding than for many other 
technology areas. Nanotechnology (i.e. technology at the extremely smal l scale of less than one 
thousandth of the breadth of a typical human hair, a scale at which the classical laws of physics no 
longer apply) has been termed as a horizontal, transverse, cross-cutting, disruptive and emerging 
technology – and it is undoubtedly a pervasive key enabling technology that has a role in many areas 
of manufacturing and an increasing number of processes and products. One challenge of 
nanotechnology is that it is ubiquitous and therefore hard to isolate, except within the scientific 
environment, e.g. of scanning tunnelling microscopes that have, since the 1980s, enabled the 
manipulation of single atoms6 7 and facilitated advances in the applications of nanotechnology. 
Nanotechnology is multidisciplinary across physics, chemistry, biology, engineering, electronics and 
photonics, materials science, medicine and other disciplines. Each of those disciplines has its own 
language and scientific methods, as well as its own gestation period for technology deployment in 
the market. For example, some developments in information and communications technologies 
(ICTs) can be commercialised within the space of months while those in nanotechnology make take 
up to, and over, ten years to come to fruition. While nanotechnology is not alone in this (another 
well-known example being biotechnology), it remains a significant challenge in technology transfer. 
Through a workshop in October 20188, a review of previous reports and additional discussions with 
experts, specific issues in nanotechnology transfer have been identified and measures to address 
them proposed. A more favourable environment for nanotechnology transfer can be created, as a 
stronger ecosystem for nanotechnology research and innovation, leading to more success in the use 
of intellectual property, in the creation of start-ups, and in the use of nanotechnology by SMEs and 
other companies in Europe through actions including the following:  
 Achieve a standardised and accepted definition of nanomaterials that can be used
throughout the EU (at least) and recognised globally, to facilitate standards and regulations,
for safety at work and for consumers, and to foster the commercial use of nanotechnology -
based processes and products.
 Increase the use of standards to both stimulate the growth of nanotechnology markets and
ensure the quality of nanotechnology products in the EU and for export.
6 Binnig, G., Rohrer, H., Gerber, Ch. & Weibel , E. Appl . Phys . Lett. 40, 178–180 (1982) 
7 Binnig, G.; Rohrer, H.  "Scanning tunnelling microscopy". IBM Journal of Research and Development 30 (4): 355–69, 1986. 
8 EC JRC workshop on Technology Transfer in Nanotechnology, 18-19 October 2018, CNR Nanotec, Lecce, Ita ly 
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 Support the whole value chain of nanotechnology through public or private funds, identifying 
the gaps where public funds are needed and recognising that nanotechnology research takes 
more time to come to fruition than many other technologies, thus requiring long-term 
commitment.  
 Foster good practices in nanotechnology transfer - in education and training, 
entrepreneurship, collaboration, communication and commercialisation.  
 Accept reasonable failure without excessive penalty in all parts of the nanotechnol ogy value 
chain but especially for nascent business ideas and entrepreneurs, and promoting actions 
that can support change of mindset.  
 Identify and finance the most promising and highest potential innovations to enable them to 
achieve demonstration, pilot production, scale-up and full-scale deployment. 
 Support hubs with a good understanding of the needs of the community, with a portfolio of 
services to drive forward nascent nanotechnology industry, that can further support 
nanotechnology-related entrepreneurship through networking, mentoring and skills 
development. Such support hubs in nanotechnology can be role models for other hubs.  
 Use horizon-scanning for high-potential innovations in nanotechnology, at EU level, 
nationally and in research organisations, identifying potential entrepreneurs who need 
support to bring their ideas forward.  
 Broaden education and training to increase both entrepreneurship and the number of people 
having complementary technological and business expertise in roles such as nanotechnology 
transfer managers and patent lawyers.  
 Require recipients of funding for early-stage commercialisation, and those aiming to set up a 
business, to complete training in intellectual property and undergo commercial coaching.  
 Develop and maintain research and technology infrastructure for nanotechnology that 
appropriately takes into consideration technology push and market pull, depending on the 
purpose of the infrastructure and user needs.  
 Support pilot plants and demonstrators as paths to bring nanotechnology research across the 
Valley of Death towards marketability, particularly in challenging areas such as 
nanotechnology, linking such facilities where appropriate and increasing good practice 
activities in awareness and interactions between stakeholders.  
 Support nanosafety and risk research, including encouraging better (interdisciplinary) 
communication.  
 Encourage the translation of nanosafety research into regulatory tools via EU and 
international cooperation. 
 Facilitate partnerships between large companies and SMEs, to strengthen the SMEs and 
make nanotechnology transfer attractive for large companies to invest in. Encourage larger 
companies to grow their relationship with SMEs in support of a stronger EU nanotechnology 
transfer environment.  
 Provide balanced and accurate information on nanotechnology for all stakeholders according 
to their needs.  
 Enhance communication between nanotechnology stakeholders, increasing awareness and 
promoting links between providers, funders, financiers, users (for a process or product) and 
consumers of nanotechnology. 
 Publicise the strengths of the EU in nanotechnology as one means of enhancing 
nanotechnology transfer, placing greater value on the history of EU nanotechnology 







1      INTRODUCTION 
 
1.1 Background 
This report considers how technology transfer in nanotechnology can be optimised, building on 
existing good practices and also learning from technology transfer of other technologies. It seeks to 
help researchers, technology managers, industry and policy-makers, by informing and guiding their 
technology transfer activities in nanotechnology. 
It is generally accepted, but not well received, that Europe is less successful in converting its research 
output into marketable products than the US, historically, and now, increasingly, Asia. To address 
this, Europe needs to create the right environment for more of its technological output to become 
commercialised. This means having the right conditions locally, nationally and EU-wide to support 
development and deployment.  
Challenges (or missions) are expected to receive about half of the anticipated EUR 100 billion funding 
for Horizon Europe9 (the upcoming EU Framework Programme 2021-2027), under its Global 
Challenges and Industrial Competitiveness pillar10. These will draw on the most advanced 
technologies, both enabling and disruptive, with nanotechnology being among the most versatile of 
those, albeit that it is still a technology in development with relatively few large-scale applications. 
Advanced materials (many at the nanoscale) are expected to become increasingly important for 
society and for business. This report therefore focuses on nanotechnology and increasing the success 
of Europe in transferring nano from being science and technology to its enabling products and 
processes, from the laboratory to the market.  
1.2  Technology transfer11 
Technology transfer is part of the innovation process; it is neither linear nor predictable, being multi -
actor and multi-stage. Technology transfer involves, inter alia, identifying and developing new 
technologies; protecting them with an appropriate intellectual property strategy, via patents and/or 
copyrights; and establishing development and commercialisation plans (e.g. licensing or company 
creation).12 Formal mechanisms of technology transfer include training, education, funded 
collaborative research and technical services. Informal mechanisms include the many and varied 
informal exchanges that take place between researchers and those applying nanotechnology, and 
structured knowledge exchange via papers and events. The most prevalent means of technology 
transfer is via published literature, patents and presentations at events (conferences, workshops, 
webinars, etc.).  
Technology transfer can mean different things to different participants in the process, with each 
engaging in part of the value chain from knowledge creation to commercialisation. For higher 
education and research institutions, technology transfer may be their goal once research and 
development is advanced, the aim being to obtain buy-in from a company (including funding) or to 
patent a technology. For a company, technology transfer often begins once research and 
development (R&D) and prototyping are complete and the technology is ready (e.g. via licensing) to 
enter production (commonly pilot-scale production before full-scale production). A schematic of 
some basic stages of technology development and commercialisation are shown below, with an 
indication of where the interests of these two groups typically lie (darker shading indicating the 
highest organisational relevance). The middle of the graphic is where the least interest is likely from 
both types of stakeholder.  
                                        
9 https ://ec.europa.eu/info/designing-next-research-and-innovation-framework-programme/what-shapes-next-
framework-programme_en  
10 https ://ec.europa.eu/commission/sites/beta-political/files/budget-may2018-research-innovation_en.pdf  
11 Adopted from the OECD Policy Platform (www.innovationpolicyplatform.org) 
12 See AUTM.net (Association of University Technology Managers) 
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In nanotechnology, this central portion (often termed “the Valley of Death”) is where many potential 
applications fail, the risk involved coming at too high a cost for either group.  
 
Figure 1: Schematic of some basic stages of technology development and commercialisation and the position of 
two main stakeholder groups 
While many of the experiences in technology transfer in nanotechnology (nanotechnology transfer) 
have parallels in technology transfer in other domains, there are specific characteristics of 
nanotechnology that merit consideration in driving it towards commercialization, starting with the 




























Research Proof of 
concept
Prototype Pilot Full-scale 
production
Higher education/research institution 
Industry 
 8 
2     FACTORS AFFECTING NANOTECHNOLOGY TRANSFER  
2.1  Nanotechnology and nanomaterials defined in the European Union context 
The EU Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has defined 
nanotechnology13 as follows: 
“Nanotechnology is the term given to those areas of science and engineering  where 
phenomena that take place at dimensions in the nanometre scale are utilised in the 
design, characterisation, production and application of materials, structures, devices and 
systems. Although in the natural world there are many examples of structures that exist 
with nanometre dimensions (hereafter referred to as the nanoscale), including essential 
molecules within the human body and components of foods, and although many 
technologies have incidentally involved nanoscale structures for many years, it has only 
been in the last quarter of a century that it has been possible to actively and intentionally 
modify molecules and structures within this size range. It is this control at the nanometre 
scale that distinguishes nanotechnology from other areas of technology.” 
In 2011, the European Commission put forward its non-binding Recommendation on the Definition of 
a Nanomaterial (2011/696/EU)14 that states, in summary: 
“ ‘Nanomaterial’ means a natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, for 50 
% or more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nanometre (nm) to 100 nm…. A material should be 
considered as (a nanomaterial) where the specific surface area by volume is greater than 
60 m2/cm3.” “…. fullerenes, graphene flakes and single wall carbon nanotubes with one or 
more external dimensions below 1nm should be considered as nanomaterials.”  
Definitions are important: EU regulations adopted after the 2011 Definition (e.g. for biocidal 
products (528/2012)) use the above recommended definition but regulations adopted before the 
publication of the EC Recommendation 2011/696/EU use a different definition (e.g. for cosmetic 
products (1223/2009) and food additives (1333/2008)). Some key regulations are listed below by 
date: 
 2017: Medical devices regulation EU/2017/745 
 2015: Novel food regulation 2015/2283 
 2012: Biocidal products regulation 528/2012 
 2011: Plastic food contact materials regulation 10/2011 
 2011: Provision of food information to consumers regulation 1169/2011  
 2009: Cosmetic products regulation 1223/2009 
 2009: Active and intelligent food contact materials regulation 450/2009  
 2008: Food additives regulation 1333/2008 
 2006: REACH (chemicals) regulation 1907/2006 
The Definition in the Recommendation (2011/696/EU) is an artificial (but useful) construct to assist in 
standardisation and regulation and has no meaning in scientific terms.15 For example, the definition 
does not cover nanomaterials that do not contain nano-sized particles but that contain nano-sized 
holes (e.g. membranes), nor does it cover metamaterials16. However, definitions are usually a 
                                        
13 http://ec.europa.eu/health/scientific_committees/opinions_layman/en/nanotechnologies/about-
nanotechnologies.htm#7 
14 http://ec.europa.eu/environment/chemicals/nanotech/faq/definition_en.htm  
15 Presentation (Technology Transfer in Nanotechnology Workshop, 18-19 October 2018, CNR Nanotec, Lecce, Italy) by 
Arnd Hoeveler, European Commission. 
16 http://www.iop.org/resources/topic/archive/metamaterials/ 
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compromise as they need to be clear for users – to have clear manufacturing and safety guidelines, 
and to be able to market a product, or supply it to another company, for example. This will be 
covered also later in this document in the section on regulation and standards.  
2.2   Nanotechnology in science and research 
Nanotechnology is multi- and inter-disciplinary. Success in solving research and technology 
challenges often lies in collaboration between disciplines. This relies on communication, and on there 
being a clear value for stakeholder, and is at the core of Open Science and the goal of widespread 
dissemination of research results within the community.  
Fundamental research is essential for the understanding of the human and material world but, of 
itself, is limited in its opportunities for technology transfer. Its focus is on the transfer of knowledge 
and expertise, through scientific journals, and student and staff mobility. Applied research, which 
may originate from fundamental research, is stronger in leading to technologies that can be 
transferred and commercialised. From the perspective of higher education and research institutions 
(HEIs and RIs), technology transfer is important, for example: in gaining recognition for new 
knowledge created; to attract corporate funding for research; as a source of income (e.g. via 
licenses); to comply with the terms of their public funding; to help local and national development; 
and to attract and retain talented staff.17 
In order to achieve these goals, priorities for higher education and research institution research  and 
technology managers include: 
 A strong and innovative team of researchers doing world-class research; 
 A continuous resource stream, from the laboratory to scale-up, for the long-term projects 
common in nanotechnology to avoid: 
o Developments being blocked for a time (or permanently) due to lack of money; 
o The loss of people (such as post-doctoral researchers) who are left with no prospects 
and no salary, and who take with them valuable know-how; 
o The lost time in training new people when funding becomes available, following the 
above loss of more experienced people; 
 For the research managers to have view across all projects, to identify those that are most 
likely to succeed, and to be able to prioritise so that the highest-potential projects have 
enough resources to be successful (in terms of furthering knowledge and/or for commercial 
purposes);  
 A dedicated technology transfer and support team in (or available to) their organisation;  
 Strong and long-term public–private sector relationships (which may also provide additional 
research funding); 
 The ability to bridge the gap between invention and the market, ensuring that  
o The product or invention is a viable proposition (e.g. can be upscaled, is patentable);  
o There is a market for it; and  
o A business can be created or established to bring it to commercialisation and being 
able to progress sufficiently far along the value chain and/or handover to others to 
commercialise; 
 The finance to achieve nanotechnology transfer goals, often a long-term financial 
commitment.  
There is a role for nanotechnology research and development organisations, such as universities and 
research and technology organisations (RTOs), in which nanotechnology research takes place to 
ensure that greater consideration is given to technology transfer and commercialisation. The root of 
this is that, in the applied context, technology is not a destination, but it can be a means to get to a 
                                        
17 See AUTM.net (Association of University Technology Managers). Additional material from Dr Corinne Monnier, CNRS 
Innovation, France.  
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destination. For researchers doing fundamental research, this not so important but for those doing 
applied research, there needs to be a discussion of the potential of the outputs of their work. For 
example, a researcher may develop a technology that appears to have a strong commercial potential. 
Their institution can and should foster a rigorous review of the materials or processes that are 
currently in place and whether innovation could be practical, cost-effective and acceptable. Some 
researchers work long and hard to develop a discovery but fail to transfer it or commercialise it 
because there is no customer or market for it, which is frustrating for them and not good use of 
public funding. Some sectors of industry are very traditional and hard to break into with 
nanotechnology, such as construction. Researchers need to consider this, and together with a 
technology transfer team, they should assess market appetite and determine the commercial and 
industrial benefit of that application upfront. If there is no evident market segment that could absorb 
that specific invention, it might be wiser to continue research activities at a fundamental level 
without raising any expectation of interest from industry. If the institutions can better characterise 
which research is fundamental and which is applied (and could be of commercial value), they will 
achieve better value for money. 
From the perspective of an International Governmental Research Organisation (IGRO), in this case 
CERN, the decision to engage in collaboration is simpler. CERN produces technology to meet its own 
needs, not for industry. To facilitate this, sometimes it enters into a consortium with other 
organisations that have the same need (as was the case for the work that led to the Medipix 
collaborations18). This may, for example, be the need for a detector chip, which the partners in the 
consortium each want it for a different application and there is therefore a common goal and no 
conflict of interest. Subsequently, the consortium may license out the technology it has  developed 
(e.g. in the Medipix case, to NASA for space dosimetry or to others for gamma cameras or 3D colour 
CT scanners). The key feature required for this to work is a collaboration agreement, an agreement 
that normally stipulates that all funders have rights proportionate to their contribution and that 
revenue should be shared according to a predefined scheme. Such CERN collaborations have also led 
to start-up companies based on detector technologies. 
For nanotechnology, there are issues in particular around the vast range of nanomaterials that are in 
the process of research and development and that could be commercialised but may or may not 
become cost-effective products; achieving upscaling of materials from the laboratory scale to 
commercial quantities; and the reluctance of businesses to take a chance on nanotechnology (in 
funding research or committing to adoption of nanotechnology in their products or processes).  
An ecosystem to accelerate the uptake of innovation in materials technology 
The EU High Level Group on Nanosciences, Nanotechnologies and Advanced Materials 
reported in October 2017 on ways to improve the uptake of innovation in materials 
technology, including nanotechnology. It focused on four key areas for action – 
characterization, modelling, pilot production lines, and standards and certification. With 
specific policy relevance to nanotechnology transfer, the HLG recommended: 
 To provide long-term support for research when applicable (ensuring continuation of 
research beyond the lifetime of individual projects) both via Horizon 2020 and 
national/regional funding; 
 To increase awareness and promote links between technology providers, technology users 
(especially SMEs), consumers and funding providers;  
 To encourage better (interdisciplinary) communication between material science and risk 
research; 
 To support the development of standards materials characterization methods via EU 
funding; 
                                        
18 https ://medipix.web.cern.ch  
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 To encourage the translation of safety research into regulatory tools via EU and 
international cooperation; and 
 To support open access when applicable. 
The report can be downloaded at https://publications.europa.eu/en/publication-detail/-
/publication/96590d0c-b867-11e7-ac8e-01aa75ed71a1  
2.3   Nanotechnology intellectual property 
In nanotechnology, and other relatively new and enabling technologies, technology transfer from 
higher education institutions is limited, the majority retaining ownership of their intellectual property 
(IP). Although innovation is strong in nanotechnology, a number of factors contribute to a low 
number of applications reaching the market, for example: 
 Researchers in nanotechnology may not be particularly motivated to seek to commercialise their 
ideas, preferring to publish. The path from that research to IP protection through patenting is 
often not appropriate, patents having the purpose of protecting solutions to technical problems, 
not to safeguard basic scientific results19.  
 Although university technology transfer offices are familiar with the mechanics of filing and 
managing intellectual property, their teams are often commercially inexperienced. Within 
academic institutions intellectual property is often filed for reputational, rather than commercial, 
reasons (also known as ‘dark IP’). 
 It can be difficult to identify the true commercial potential of nanotechnology research and 
development (R&D), value that may be achieved later e.g. through licensing or a start-up. 
European researchers have less of a tradition of using their intellectual property for commercial 
purposes than in other countries, particularly the US. For example, in the recent EU NanoData 
study20, it was seen that the US led for nanotechnology patenting in the period from 1993 to 
201321 for the sectors of construction, energy, environment, health, ICT22, manufacturing, 
photonics and transport23, with Japan in second place in all except health (where it was 
Germany).  
 Researchers who consider transferring their technology to industry often place an unrealistic 
value on knowledge that is fresh from the laboratory bench and only entering early -stage 
development. This can jeopardise their engagement with industry and damage potential 
relationships. It is critical in complex areas such as nanotechnology for the researcher and/or 
technology manager to know both the potential of their technology (technology push) and the 
needs of potential customers (market pull) and to have a strong plan to achieve (either 
themselves or through others) proof of concept, prototyping and pilot production so that the 
technology can, in due course, enter full production as a commercial product or process.  
 In the past, there has been evidence of a ‘land-grab’ of intellectual property in nanotechnology, 
where countries or companies undertook preventive patenting in protecting materials without 
knowing what their future uses could be. Now that there is a better unde rstanding of 
nanotechnology, there can be better early-stage reflection on the potential value of IP and 
whether or not to patent.  
                                        
19 Korhonen and Simmelvuo at the Nanoforum workshop in Helsinki, 2007 
https ://www.nanowerk.com/nanotechnology/reports/reportpdf/report73.pdf  
20 NanoData s tudy for EC DG-Research and Innovation under Framework Service Contract NMP4-FC-2013-ND0000, 
conducted by the Joint Institute for Innovation Policy (www.jiip.eu)  
21 Data  used were for country of applicant. Source PATSTAT database, copyright European Patent Office (EPO)  
22 The greatest number of nanotechnology patent applications by sector in 1993-2013 was in ICT, both globally and for the 
EU and EFTA countries. 
23 These were the eight sectors considered in the NanoData s tudy. 
 12 
 Many in industry, particularly SMEs, do not have sufficient understanding of intellectual property 
and its exploitation and lack broader commercial skills. Unlike larger companies, SMEs also have 
no system of support for such business aspects.  
 Nanotechnology projects tend to be long-term with a high level of expenditure before any 
turnover is achieved. For certain industries (e.g. transport, energy), products need to have a long 
lifetime before replacement is needed, making the proof of product stability and durability very 
important, also raising the length of time to market and the cost of commercialisation.  
 Nanotechnology development requires both breadth and depth of knowledge without which it 
struggles to move forward to commercialisation. For example, in France, there is a lack of the 
SMEs to bring products forward sufficiently to engender the interest of large companies to 
manufacture on a large scale. For nanotechnology, most of the knowledge is either in small and 
highly-specialised firms or in very large ones that cover multiple domains, and there is often a 
missing part of the value chain that would link the one to the other. Sometimes this is achieved 
by acquisition or licensing but often the small company limps on and does not reach profitability. 
Medium-sized nanotechnology firms do not generally play the key role as translator of new 
knowledge between public research and industry.24  
In terms of recommendations, the understanding of nanotechnology transfer by academic 
researchers at the start of their research careers could be greatly enhanced through a short period of 
training (“nano-IP 101”) in intellectual property including patents, copyright, brands, trade secrets 
and trademarks, licensing agreements and non-disclosure agreements. This would help them to 
know when to patent, copyright or protect a trade secret and to avoid the loss of IP through ill-timed 
publication or other dissemination. It would increase the overall understanding in the research 
community and enable better nanotechnology transfer. Not all will want to use their knowledge 
output commercially (not should they) but those that are more business-oriented will have a greater 
chance of their ideas flourishing and reaching a market value via appropriate and well -timed 
nanotechnology transfer. Such training could be available for all researchers, professors, senior 
lecturers and grant co-ordinators in receipt of EC (or national) funding, every three to five years for 
repeat recipients of funding. There are already some examples of good practice (e.g. in short 
courses) that could be developed and implemented more widely in Europe.  
Some EU schemes, such as the SME Instrument Phase 2 grant, insist on coaching for SMEs, in this 
case 12 days. SMEs that have experienced such coaching advocate making it a condition of receipt of 
any EU funding intended to support early-stage nanotechnology commercialisation. Similarly, such 
coaching would be of great benefit to academics and other researchers considering starting a 
business. Ideally, especially where the participants are from current or potential start-ups and SMEs, 
such training would have an international focus with participants benefiting from sharing their 
experiences to date and the problems they have had, in a mutual learning environment, as well as 
gaining a better understanding of international intellectual property systems. For more developed 
but still early-stage businesses, courses for advanced IP uses and IP negotiating skills would be 
beneficial. Continuing from there, as businesses become more advanced, courses could include: 
‘scaling an organisation’, developing management systems for operational and commercial 
control/effectiveness; options for growing international sales; etc. the aim being to create a robust 
commercial pipeline in Europe based on nanotechnology R&D.  
While there would be a cost involved in providing intellectual property/commercial skills courses 
(and effort to find sufficient mentors and business coaches), this would be offset by the increased 
probability of a successful nanotechnology business emerging.  
It is noticeable that the majority of both technology transfer managers and patent lawyers, operating 
in (not only) nanotechnology, have backgrounds in the technology rather than in the commercial 
                                        
24 Corine Genet, Khalid Errabi, Caroline Gauthier. Which Model of Technology Transfer for Nanotechnology? A Comparison 
with Biotech and Microelectronics. Technovation, Elsevier, 2012, 32 (3-4), p. 205-215 
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world, which can be to the detriment of technology transfer. Complementary skills from technology 
and business are needed and the education and training system should foster those skills, and 
technology transfer offices make them a requirement among staff.  
2.4   Entrepreneurship in nanotechnology 
Entrepreneurship in the EU is low compared with other countries, with self-employment being seen 
as attractive by only about a third of Europeans compared to half of Americans and Chinese 25. Failure 
is not well-received in Europe, as evidenced by a longer recovery time and likely reduced future 
investment following failure, relative to the US, for example. In Europe, public sector researchers 
often see no route by which to return to academia or a research organisation once they take time 
out to commercialise their invention or discovery. They are prevented from pursui ng technology 
transfer because they fear that their departure will be permanent and are not willing to take that 
risk. Europe could better reward economic impact in applied science and enable researchers to move 
more freely between research and business environments during their careers.  
The EU recently highlighted, in the context of the digital transformation and education 26, the need to 
boost entrepreneurial competences and an entrepreneurial mind-set for both new ventures and 
existing businesses in transformation. This requirement surely extends to all areas of transformative 
technologies and new materials, including nanotechnology, and can be enhanced by broadening 
education and training to stimulate and support entrepreneurship. Furthermore, entrepreneu rs and 
those looking to start a business or licence out their technology need to be supported via training in 
intellectual property and commercial coaching. In particular, recipients of funding for early -stage 
commercialisation should be required to complete such training and coaching within the conditions 
of their funding. 
One additional initial step is to identify potential entrepreneurs who need support to bring their 
ideas forward. Some academic institutions are proactive in this (e.g. the University of  Manchester 
and its subsidiary Graphene Enabled Systems Ltd), creating environments to bridge the gap around 
demonstration and to reduce the risks for investors (see first box below). At EU level, in ICT, the 
European Commission has established an Innovation Radar to identify high-potential innovators and 
their innovations coming from EU publicly-funded research (see second box below). 
Graphene Enabled Systems Ltd 
Graphene Enabled Systems Ltd is a wholly-owned subsidiary of the University of Manchester, UK. Its 
mission is to create a series of successful graphene ‘spin–out’ businesses. The spin-outs license the 
University’s portfolio of intellectual property (IP) in graphene and other two-dimensional materials 
but develop the IP for their own applications. To reduce risk for investors, it places high importance 
on high-quality product demonstrators, strong business plans (with a clear exit strategy for each 
spin-out) and early-stage management support. It takes no equity in the spin-outs.  
Graphene Enabled Systems sees its role as bridging the gap between the university and industry, 
facilitating the move from lower to higher technology readiness levels (TRLs) 27, from research 
outputs at TRL1-3 to demonstrated technologies at TRL5-6 that are ready to make the transition to 
                                        
25 Only 37% of Europeans would l ike to be self-employed, compared to 51% of people in the US and China. 
https ://ec.europa.eu/growth/smes/promoting-entrepreneurship_en 
26 https ://ec.europa.eu/education/sites/education/files/digital-education-action-plan.pdf 
27   Technology Readiness Levels :  1 - basic principles; 2 - technology concepts; 3 - experimental proof of concept; 4 - 
technology va lidation in lab; 5 - technology va lidated in real environment; 6 – technology demonstrated in real 
environment; 7 – prototype demonstration in operational environment; 8 – system complete and qualified; and 9 – 




industry. The team at Graphene Enabled has skills including technology evaluation; project 
engineering; market analysis and market engagement - many team members are sourced from 
industry. It also draws on experts to assess potential product ideas, retaining in the pipeline only 
those that merit further investment, with others being returned for further research to be 
undertaken; some licensed out directly; some kept for further consideration; and the rest rejected as 
unfeasible. The selected product ideas are supported through additional technical evaluation and 
market studies. In the following stage, ideas that are not rejected due to commercial, operational or 
technical issues progress to the demonstrator and business planning stages.  
Spin-outs to date include: 
 Atomic Mechanics - proprietary sensors, touch-interfaces and actuation devices based on 
graphene-polymer membranes - www.atomic-mechanics.com 
 Gra-fine - high performance elastomers enhanced by nano-materials – www.gra-fine.com 
 Graphene Water technologies - equipment and membranes to clean polluted water 
 ‘The Electronic Nose’ spin-out, a chip based VOC sensor technology using functionalised 
graphene membranes. 
For further information, see https://www.graphene-enabled.com  
 
 
The EU (ICT) Innovation Radar 
The Innovation Radar is an initiative of the European Commission focused on the identification of 
high-potential innovations, and the key innovators behind them, in FP7, CIP and Horizon 2020 
projects in information and communications technologies (ICT). It supports innovators through a 
range of potential targeted actions to help them fulfil their potential in the market. It is an initiative 
that involves: 
 Assessing the maturity of innovations developed within FP7, CIP and H2020 projects and 
identifying high potential innovators and innovations (using a model developed by JRC-
IPTS); 
 Providing guidance during the project duration in terms of the most appropriate steps to 
reach the market; and 
 Supporting innovators through EU (and non-EU) funded entrepreneurship initiatives to 
cover specific needs in areas including networking, access to finance, and intellectual 
property issues. 
The EU Innovation Radar covers all ICT research and/or innovation projects launched under Horizon 
2020, FP7 and CIP supports, so innovators participating in any of these specific ICT projects can 
benefit. The potential innovations and/or innovators are identified with the help of external 
innovation experts and based on objective criteria discussed in the project reviews. Top innovators 
are promoted through the Digital Single Market webpages to increase their visibility with potential 
investors, users and buyers. 
  See https://ec.europa.eu/digital-single-market/en/innovation-radar  
 
While education in science is about achieving at the highest level, entrepreneurship is about 
creativity and exploration of ideas. Entrepreneurs therefore need to be given the space to fail, as well 
as to succeed, which requires a change of mindset within the system. Approaches to 
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entrepreneurship vary from one EU country to another, France being one of those that is promoting 
entrepreneurship from school age on, including at doctoral level.28  
The role of small and medium-sized companies in nanotechnology is generally limited to the initial 
generation or adoption of nanotechnology e.g. in start-ups from universities or spin-offs from larger 
companies. The EU has over time been increasing support for an enterprise -focussed environment 
for nanotechnology and advanced materials: under Horizon 2020, for example, there is support for 
Open Access Pilot Line projects29 in nanocomposites30,31 and nanopharmaceuticals32, and Open 
Innovation Test Beds33. Such initiatives could further support nanotechnology-related 
entrepreneurship through enhanced measures for networking, mentoring and skills development 
(technical and non-technical skills).34 
EU Open Innovation Test Beds35 
EU Open Innovation Test Beds offer access to physical facilities, capabilities and services required 
for the development, testing and upscaling of nanotechnology and advanced materials in industrial 
environments. The aim is to bring nanotechnologies and advanced materials within the reach of 
companies and users, to advance from validation in a laboratory (TRL4) to prototypes in industrial 
environments (TRL7). The Test Beds focus on testing and upscaling equipment, as well as 
modelling, characterisation, regulatory and technology advice, for innovative technology products 
that have already gone through the research process and are at ready for upscaling. 
The funding under Horizon 2020 is to support the establishment of, or upgrading of existing, public 
and private test beds, pilot lines, and demonstrators. Private entities can apply for funding, as well 
as research and technology organisations, research centres or higher education establishments. 
The test beds are to be typically run by for-profit organisations with users coming from industry, 
including SMEs, innovators and start-ups. About 20 Open Innovation Test Beds are excepted to be 
created and EU support is being offered under Horizon 2020 NMBP calls scheduled in the following 
areas: lightweight nano-enabled multifunctional materials and components; safety testing of 
medical technologies for health; nano-enabled surfaces and membranes; bio-based nano-
materials and solutions; functional materials for building envelopes; and nano-pharmaceuticals 
production, as well as materials characterisation and modelling.  
Open Innovation Test Beds can help by providing a single entry point to facilities and services 
across Europe; reduce costs for both industry and users; offer harmonised conditions for testing, 
upscaling, characterisation and modelling; create faster maturation of products for faster market 
entry; give early-stage access to intelligence on EU regulations; and offer easier marketability of 
                                        
28 In 2013, the French Parliament adopted the national principle that all children should acquire knowledge, skills and 
competencies to continue with further education, choose their own professional career and actively participate in civil life. 
In l ine with this, entrepreneurship is a  cross-curricular objective in school education in France and is integrated in various 
optional subjects as well as being part of the compulsory subject Economic and Social Sciences during the last two years of 
education. This is continued in higher education with initiatives in French Doctoral Schools (e.g. MSc in Entrepreneurship at  
EDHEC Bus iness School, Lille).  
29 For example, https://cordis.europa.eu/programme/rcn/665001_en.html, 
https ://cordis.europa.eu/project/rcn/194436/factsheet/en, https://cordis.europa.eu/project/rcn/194436_en.html  
30
 http://www.platform-project.eu; http://www.izadinano2industry.eu  
31 https ://www.acciona-construccion.com/innovation/innovation-projects/materials/oasis/ 
32 http://nanofacturing.eu/about/ 
33 Open Innovation Test Beds are to be physical facilities, established in at least three Member States / Associated 
Countries, offering technology access and services to bring nanotechnology and advanced materials within the reach 
of companies and users in order to advance from validation in a  laboratory (TRL4) to prototypes in industrial 
environments (TRL7).  
34 NanoData study for EC DG-Research and Innovation under Framework Service Contract NMP4-FC-2013-ND0000, 
conducted by the Joint Institute for Innovation Policy (www.jiip.eu) 
35 https ://ec.europa.eu/jrc/sites/jrcsh/files/24012018-innovationweek-bowadt_en.pdf  
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products in Europe (e.g. non-European products to be tested in accordance to EU regulations to 
enter the market). OITB are expected to facilitate access of European SMEs along product supply 
chains.  
Eligible costs under Horizon 2020 can include: acquisition, adaptation, installation and calibration 
of upscaling and testing equipment; demonstration cases; networking activities between Open 
Innovation Test Beds and similar initiatives; communication and dissemination activities; and 
design and development of services infrastructure: technology expertise; legal / regulatory 
expertise; modelling tasks; characterisation tasks; facilitation of access to funding for test bed 
customers. 
After the end of EU funding, the Test Beds will have to operate autonomously using the revenues 
of the services they provide. 
For further information, see http://www.nmpteam.eu/open-innovation-test-beds-guidelines/  
 
 
PLATFORM – Open Access Pilot Lines, an example 
PLATFORM is a research project funded under the H2020 Framework Programme to develop open 
access pilot lines for the industrial production of bucky-papers, carbon nanotube (CNT)-treated 
prepreg and CNT-doped non-woven veils for composite applications in sectors such as aerospace 
and automotive. The project builds on the success of two FP7 Framework Programme projects - 
ELECTRICAL and SARISTU – that developed methods to manufacture CNT-reinforced 
multifunctional composites compatible with industrial manufacturing processes.  
The PLATFORM project core consists of 12 partner organisations (public and private) from six EU 
countries (ES, PL, BE, EL, IT and the UK) covering the entire value chain of the above product lines: 
nanomaterial supplier(s); experienced research and technology organisations (RTOs) with existing 
nanomaterial pilot plants (such as Tecnalia in Spain http://www.tecnalia.com, the coordinator of 
PLATFORM); and European composite material suppliers and end users from e.g. the aeronautical 
and automotive sectors.  
The consortium comprises five RTOs, three large enterprises and four SMEs across the value  chain 
for the development of the production facilities for new nano-enabled products. PLATFORM 
provides SMEs with open access to these facilities for direct product purchase, product 
development, collaborative research and training. The SMEs are also offe red a wide range of 
supports ranging from nanocomposite development, production and integration and extensive 
testing facilities to support for business development and market exploitation.  
The companies involved in PLATFORM are experienced in research and development and several 
have been involved in previous projects using EU funding. They include Adamant Composites 
(www.adamant-composites.gr); Carbures – an engineering and manufacturing company in 
composites structures, specialising in carbon fibre (www.carbures.com); and Nanocyl -  a 
technology SME focused on nanocomposite product development (www.nanocyl.com). PLATFORM 
will automate steps in the manufacturing processes, introduce novel in-situ characterisation 
methods and incorporate instrumentation for nanomaterials and nanomaterials -based 
intermediates. The main goals are the higher quality of the products, improved process 
repeatability and yield whilst reducing lead times and product costs.  
For further information, see http://www.platform-project.eu 
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Entrepreneurs need to know their technology and what it offers in technological terms (technology 
push) but also its potential market and the challenge the technology can solve for potential 
customers, i.e. the reason that a customer will want to buy it (market pull) and therefore the reason 
that a manufacturer will want to make it. A particular concern for nanotechnology is that 
entrepreneurs may engage in the application of nanotechnology without a full understanding of the 
technology, including potential risks and how they should be addressed.  
2.5    Regulation and standards for nanomaterials 
2.5.1   Legal aspects and Recommendations 
Since 2007, nanomaterials must comply with the EU regulatory framework for chemical substances: 
REACH - the Registration, Evaluation, Authorisation and restriction of Chemicals in Europe. However, 
that regulation is not specific to nanotechnology or nanomaterials as that is not its purpose. 
Nanomaterials are covered by the definition of a "substance" in REACH, but there is no  explicit 
reference to nanomaterials. In October 2017, the European Commission published its proposal, 
which is open for consultation and is to be implemented from 1 January 2020, to amend the REACH 
Annexes to address ‘nanoform substances’. 36 
In 2011, the European Commission made its Recommendation on the Definition of Nanomaterial 
(2011/696/EU) 37, which, in brief, states that:  
“ ‘Nanomaterial’ means a natural, incidental or manufactured material containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for 50 % or more of the particles 
in the number size distribution, one or more external dimensions is in the size range 1 nm - 100 nm…. 
A material should be considered as (a nanomaterial) where the specific surface area by volume is 
greater than 60 m2/cm3.” and “…. fullerenes, graphene flakes and single wall carbon nanotubes with 
one or more external dimensions below 1nm should be considered as nanomaterials.” 
This non-binding Recommendation has been used since 2011 in regulatory situations that needed to 
define the term ‘nanomaterial’. Some are listed in the table below, together with regulations that 










                                        
36 https ://echa.europa.eu/-/echa-welcomes-improved-clarity-on-nanomaterials-in-the-eu-member-states-vote-to-amend-
reach-annexes 
37 Recommendation on the definition of a nanomaterial (2011/696/EU) https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX:32011H0696  
 18 
Table 1: Overview38 of selected EU regulations having relevance for nanomaterials (with X indicating 
where they contain a specific provision for nanomaterials), ordered by year (oldest first)  
 
*Labelling of novel foods and food additives containing nanomaterials is required under the EU Regulation on the Provision 
of Food Information to Consumers 1169/2011. 
In the absence of an agreed definition of nanomaterials, the above being only an EU 
Recommendation, different definitions are currently in place across sectors and countries, not only 
the headline definitions but also the exemptions and thresholds that underpin their application for 
regulatory approval. This creates barriers to market access in terms of resources and skills needed to 
complete regulatory approval processes across sectors and territories. These barriers are particularly 
difficult for SMEs to overcome, both in knowledge and financial terms. For companies of all sizes, the 
added cost of diverse regulatory pathways will often exceed the cost-benefit threshold for market 
decisions.  
At the international level, the International Organisation for Standardisation (ISO) is responsible for 
the standardisation of nanotechnologies with its TC 229. In Europe, the equivalent group is the 
European Committee for Standardisation committee on nanotechnology (CEN/TC 352) which has, for 
example, a working group on health safety and environmental aspects. While standardisation bodies 
have nanotechnology committees, nanotechnologies are also cross-sectoral and considered in other 
CEN and ISO working groups. 
Standards are market driven and have a significant role in making nanotechnology more accessible to 
users, with the involvement of industry essential in developing and deploying relevant standards, but 
more needs to be done in facilitating the use of nanomaterials in manufacturing environments. Data 
sheets, handling advice and/or guidance on the use of materials in a real factory environment are 
urgently required by manufacturers. While issues around definitions need to be resolve d as a matter 
of urgency, it could be that interim measures and documentation that industry can use can be put in 
place until full resolution is achieved.  
 
 
                                        
38 Source: “Regulatory Aspects of Nanomaterials in the EU” by Rauscher H, Rasmussen Kand Sokul l -Kluettgen B, Chemie 
Ingenieur Technik 89, No. 3, 224–231 (2017), doi : 10.1002/ci te.201600076. The information has been updated to reflect the 
coming into law of the Medica l  Devices  Regulation EU/2017/745. 
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The EU Joint Initiative on Standardisation  
The Joint Initiative on Standardisation aims to further drive innovation through working together 
(research, industry, standards authorities) for the most appropriate standards and to raise 
awareness of the importance of standards. It is undertaking fiftee n Actions to modernise the 
European standardization system.  
For example, the EU Joint Research Centre (JRC) is leading Action 2: To establish a sustainable 
system that encourages the natural collaboration between researchers and innovators with the 
European Standardisation System, and allows for the smooth uptake of research and innovation 
outputs into standardization 
The three work-packages are to: 
1 - Further develop and exploit Foresight Mechanisms - Putting Science into Standards initiative, 
bringing the scientific and standardisation communities closer together by anticipating and bringing 
new issues requiring standards to the standardisation community. So far, its work has included 
nanotechnology-related activities such as looking at quantum technologies and aiming to generate 
an overall quantum awareness among businesses and industry and to see where standards are most 
needed/relevant.  
2 - Deepen Research – Standardization Integration - Foster and exploit the role of standardisation in 
Horizon Europe – including promoting market uptake of Horizon Europe projects outputs facilitated 
through standardization; promoting and disseminating best practice across innovation-related 
initiatives and networks to address standardisation as part of their Strategic Research Agendas; to 
coordinate the appropriate representation of professionals and researchers in standardisation 
activities; enhance the impact of pre- and co-normative research into R&I. 
3 - Introduce standardization in the European Innovation Eco-system – Including to engage 
researchers and innovators via success stories, awards and illustrations of the benefits of 
standardization; and encourage industry research groups to include standardization in projects.  
For further information, see http://ec.europa.eu/growth/content/joint-initiative-standardisation-
responding-changing-marketplace-0_en  
 
2.5.2   Research aspects 
Support for regulation and standards comes from research into materials properties and their effects 
on the human and natural environment. While such research is useful, it is essential that resources 
be well used by minimising the duplication of effort. In addition, the outcomes of research need to 
have a purpose and a value. There are many risk studies of small groups of materials in specific 
situations (e.g. the health risks of carbon nanotubes should they become freely mobile in the 
environment) but life cycle assessments on nanotechnology are few, have restricted scope and make 
many assumptions. In the industrial environment, assessments are undertaken on pilot plants rather 
than full-scale industrial plants. There is therefore a lack of information from production to disposal 
or recycling. However, what businesses need is the best available information on which they can act 
in using nanomaterials. One approach would be to not wait for precise data on every nanomaterial in 
every situation but rather to implement the use of the materials with guidelines (at factory floor 
level) based on the best available information from the different sciences involved (physics, 
chemistry, toxicology, environmental sciences, engineering, biology, etc.). The challenge in this is 
recognised - there being the basic problems that the sciences do not speak the same language but 
also that business does not know what to communicate to other businesses or to customers - but it 
would enable industry to have a better environment in which to work, given that it is already using 
nanomaterials and has been for decades.  
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The NanoData study39 highlighted that it is forecast that a very large number of new and modified 
nanomaterials are likely to emerge in the next few years, mainly driven by bio-applications, as in the 
health sector, for example. It is forecast that funding (public or private) will not meet the growing 
need for research, characterisation and testing (including research on testing protocols and 
monitoring). In addition, there will be severe pressure on data collection and processing systems, 
with improvements needed to be able to cope with very high volumes of data, greater than can be 
managed currently using ICT. Streamlining of efforts needs to be ensured (including standardisation 
of data capture) and duplication avoided. 
The view from the EU High Level Group on Nanosciences, Nanotechnologies and Advanced 
Materials40 is also relevant here, namely to:  
 Encourage the further translation of safety research into regulatory tools via European and 
international cooperation;  
 Encourage the creation of new opportunities for a competitive edge in innovation and 
market expansion by safe-by-design approaches if relevant;  
 Improve networking between safety centres;  
 Encourage better communication between material science and risk research (following an 
interdisciplinary approach);  
 Continue support for standardisation through funding at Horizon 2020 and national level. 
 
2.6   Nanotechnology infrastructure and the creation of platforms, networks and hubs 
Infrastructure is part of the commercial value chain of nanotechnology, which starts at the laboratory 
bench and results in a product or process being on the market. In general, two different types of 
infrastructures can be identified depending on the TRLs (technology readiness levels) on which they 
focus – research infrastructure and technology infrastructure (see boxes below).  
Research Infrastructures41: Facilities, resources and services that are used by the research 
community to conduct research and foster innovation in their fields (mainly TRLs from 1 to 4).  
Examples of research infrastructures (RIs) include: 
• Major scientific equipment (or sets of instruments); 
• Collections, archives or scientific data; and  
• E-infrastructures (data, computing systems, communication networks.  
RIs are generally domain-specific, and can be single-site or distributed. RIs serve mainly 
researchers, both from academia and industry (including SMEs) and offer free access to facilities, 
technologies and services. Where relevant, they can be used for education or public services.  
The European research infrastructure landscape comprises: 
• Intergovernmental research infrastructure: well -established research infrastructure 
supported by the Member States and others (e.g. EMBL, CERN, ESA);  
• New pan-European research infrastructure: research infrastructure listed in the ESFRI 
Roadmap (see box below); and  
• Networks of national and regional research infrastructure open to all European researchers 
from both academia and industry. These networks of research infrastructure are promoted 
                                        
39 NanoData s tudy for EC DG-Research and Innovation under Framework Service Contract NMP4-FC-2013-ND0000, 
conducted by the Joint Institute for Innovation Policy (www.jiip.eu) 
40 https ://publications.europa.eu/en/publication-detail/-/publication/96590d0c-b867-11e7-ac8e-01aa75ed71a1 
41 https ://ec.europa.eu/research/infrastructures/index.cfm?pg=home  
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by the European Commission through Integrating Activities for Advanced Communities 
(INFRAIA)42. 
 
Technology Infrastructures43: Facilities, equipment, capabilities and support services required to 
develop, test and upscale technology to advance from validation in a laboratory (TRL 4) to 
prototypes in industrial development (TRL 7), including: 
• Pilot lines; 
• Digital innovation hubs; 
• Open innovation testbeds; 
• KET centres (centres for key enabling technologies); and 
• Demonstration sites of field labs. 
Technology infrastructures (TIs) may be sector-specific or technology-focused and can vary in size 
and capacity, but they should adapt easily to changing industrial needs and fast technological 
developments. 
They serve mainly companies, including SMEs, that seek support to develop and integrate 
innovative technologies towards commercialisation of new products, processes and services, whilst 
ensuring feasibility and regulatory compliance. 
In considering any investment in infrastructure, particular attention must be paid to the parts of the 
value chain it is to address. If the aim is to facilitate research, multiple research i nstruments44 45 may 
be needed. If the aim is to enable technology transfer and commercialisation, a pilot plant 46 or 
process development facility may be seen as appropriate. The next step would be a demonstration 
plant, to be able to test the logistics, the advantages and possible drawbacks and challenges of 
larger-scale operations. In addition to their primary aims, some research infrastructures address 
education and training47. 
The European Strategy Forum on Research Infrastructures (ESFRI) 
Since 2002, the European Strategy Forum on Research Infrastructures (ESFRI) has been 
supporting the development of EU research infrastructure. It develops strategic roadmaps, 
identifying the potential for new pan-European research infrastructures or major upgrades to 
existing ones, across sectors including energy, environment, health and food, physical sciences 
and engineering, social and cultural innovation, and digital. Research infrastructure on current or 
past roadmaps include solar telescopes, systems for scientif ic and heritage collections, 
synchrotron radiation facilities, advanced computing partnerships, e -infrastructure for 
biodiversity and ecosystem research, structural biology infrastructure, and global environmental, 
                                        
42 http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-infrastructures_en.pdf  
43
 Link to the SWD on Technology Infrastructures  
44 See instruments from the EU Horizon 2020 Work Programme for Research Infrastructures 
(https ://ec.europa.eu/programmes/horizon2020/en/h2020-section/research-infrastructures-including-e-
infrastructures  




47 For example, see Renatech, the French network of high-end facilities in the field of micro & nanotechnology coordinated 
by CNRS. https ://www.renatech.org/en/qui-sommes-nous/ 
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seafloor and European plate observatories.  
The mission of ESFRI is to support a coherent and strategy-led approach to policy-making on 
research infrastructures in Europe, and to facilitate multilateral initiatives leading to the better 
use and development of research infrastructures, at EU and international level. Delegates are 
nominated by the research ministers of the Member States and Associate Countries and work 
together to develop a joint RI vision and a common RI strategy to reduce fragmentation and 
waste of RI resources across Europe, aiming for the most up-to-date research infrastructures, 
responding to rapidly-evolving science frontiers, and advancing knowledge-based technologies 
and their use. 
ESFRI is not a funding body: funding for research infrastructure comes at EU level currently, i n 
large part, from H2020 under the Excellent Science pillar (EUR 2.4 billion from 2014-2020) and 
includes e-infrastructure.  
For further information, see www.esfri.eu  
Infrastructure can only enhance technology transfer if there is sufficient demand from potential 
users. There must also be the right infrastructure to meet all user needs, whether the research 
infrastructure is funded publicly or privately (or jointly). Any gap in the nanotechnology value chain 
will result in the technology not being commercialised. Therefore, full consideration needs to be 
given to the purpose of infrastructure from the aspects of both technology push and market pull, as 
with all other parts of the value chain.  
Pilot production, through pilot plants and demonstrators, has been identified as a key vector in 
bringing research across the Valley of Death towards marketability, particularly in high-cost, high-risk 
areas such as nanotechnology and other key enabling technologies (see box below). Demonstrators 
are greatly under-rated: a good demonstrator is highly effective in raising money and winning 
business and must be designed not only to show the capability of the technology but also to 
demonstrate a viable pathway to manufacturability. The success of a demonstration plant or a 
flagship demonstration project can either (or both) test the workability of an innovation under 
operational conditions and drive the removal of institutional and social barriers standing in the way 
of an innovation (by promoting or aligning the discussion and development of policies and practices 
to enable the innovation to be commercialised and open its path to the market).  
Pilot production  
Crossing the Valley of Death requires a diverse set of (pilot production) activities linking 
technological development and the first commercialization of a product. These activities address 
the development of technologies (manufacturing and product oriented), as well as more 
organisational and market-oriented activities. This stage of the innovation process has a systemic 
nature and these multi-disciplinary activities show strong inter-linkages. Pilot production activities 
do not automatically lead to full production, this being especially true within SMEs.  
The following activities are considered pilot production activities: 
 Research and development to validate both technology/component/subsystem 
development in laboratory environment and “transferability” to pilot manufacturing;  
 Set up of pre-commercial pilot manufacturing system operated by one or multiple industry 
partners, including participation of external bodies like SMEs and research organisations;  
 Production of first pre-commercial products and prototypes for testing and validation of 
the product by customers and of the manufacturing process (including cost-efficiency); 
 Adjusting product design based on pre-commercial manufacturing; 
 Creation of market relationships with lead customers giving them access to new 
technologies, preparing the company for full commercialisation; 
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 Business development with internal and/or external investors; and 
 Preparation of the internal and external organisation for full manufacturing, including the 
value chain development. 
Pilot production, often termed ‘pilot lines’ and ‘demonstrators’, are crucial in the problems of 
crossing the Valley of Death. Pilot lines are pivotal in transforming the outcomes of technological 
research into competitive manufacturing, albeit that they are also capital intensive. Often 
policymakers are reluctant to support (high risk) pilot production facilities, regarding such 
investment as the responsibility of entrepreneurs or companies. But the economic risk is often too 
high for investors and companies, especially for SMEs and start-ups. [Nanotechnology] markets are 
still too uncertain and [the technologies] too complex to make the large investments needed to 
better understand and justify potential costs relative to revenues. Without public support, the 
consequence of such an impasse is that innovative nanotechnology solutions (for e.g. climate 
change, ageing and new jobs, and to address environmental challenges) will not reach the market. 
Society will therefore not benefit from the vast public investments in research and development up 
to lower TRLs if the investment to reach higher TRLs is missing. Indirectly, the innovation ecosystem 
and downstream industries will not benefit from the opportunities from [nanotechnology], 
weakening the economy at large. 
Adapted from the Final Report of the mKETs-PL consortium (funded by the European Union), but 
including additional original material from this study/workshop 
See: http://www.mkpl.eu/fileadmin/site/final/mKETs_D7_final_report.pdf  
It is also essential:  
 To avoid duplication of facilities and effort, particularly under the current budgetary 
constraints;  
 To optimise the working of facilities through exchange of best practice, developing 
interoperability of facilities and resources and the training of the next generation 
researchers; and  
 To encourage an appropriate and practical level of open access, for users from all sectors.  
In its report of October 2017, the EU High Level Group on Nanosciences, Nanotechnologies and 
Advanced Materials made recommendations on pilot production lines (together with 
characterization, modelling, and standards and certification).48 It particularly encouraged the 
promotion of the interconnection of pilot facilities and open innovation test beds (supporting open 
access); developing the system of test beds to cover the full range of value chain services (modelling, 
characterization, safety and business liaison services); increasing awareness and promoting links 
between technology providers (the pilots), users (SMEs), consumers and funding providers; and 
providing events about the use of pilot plants (for SMEs) and matchmaking/brokerage events and 
coaching at regional levels. 
NFFA-EUROPE  
NFFA-EUROPE – nanoscience foundries and fine analysis – is an open access research infrastructure 
for experimental and theoretical nanoscience funded under Horizon 2020 (Sept 2015 – Sept 2019). 
It is coordinated by CNR-IOM (Istituto Officina dei Materiali (IOM) of the Italian National Research 
Council (CNR)).  
NFFA-EUROPE is a platform to facilitate multidisciplinary research at the nanoscale extending from 
synthesis and characterization to theory and numerical simulations. Advanced infrastructures, 
                                        
48 https ://publ ications .europa.eu/en/publ ication -deta i l /-/publ ication/96590d0c-b867-11e7-ac8e-01aa75ed71a1  
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including synchrotron, free electron laser and neutron radiation sources, are integrated in a multi -
site combination with state-of-the-art laboratories across twenty partners49 for reproducible 
nanoscience research, to enable European and international researchers from diverse disciplines to 
carry out advanced projects impacting science and innovation. Half of the partners are nano -
foundries that are co-located with analytical large-scale facilities. 
Access to the facilities is through a Single Entry Point (SEP) portal with the assistance of the 
Technical Liaison Network (TLNet). NFFA-EUROPE offers transnational access, with 80% of access 
for EU Member States and Associated Countries, with support also for travel and subsistence. The 
results of the research have to be disseminated (except in the case of SMEs).  
The technology transfer relationship between NFFA-EUROPE and industry is different from that 
between scientific institutions and companies. In accessing NFFA-EUROPE, companies ask the 
research infrastructures for solutions and the patents and prototypes created by the RIs are 
brokered to industry. In this way, they develop a type of shared goal, the RI to develop something 
new (e.g. to build an instrument) and the company to sell a new product (e.g. using that instru ment 
in production). Industry uses the specific skills of RI-researchers (who routinely work with external 
users), access state-of-the-art, highly specialized instrumentation, have access to the RI for early 
stage basic research (often in cooperation with academic teams), engage with them in testing 
innovative developments, new protocols, and gain training and expertise.  
For further information, see https://www.nffa.eu/about/  
There is evidence that currently publicly-funded facilities are under-used while industry is looking for 
exactly those types of facilities but cannot access them due to State-aid rules, a situation that need 
to be revisited and revised.  
Access to research infrastructure at the EC Joint Research Centre 
The EC Joint Research Centre (JRC) hosts 37 physical research infrastructures with a potential of 
opening to external users (out of a total of 57 facilities). This it does while:  
 Ensuring a fair and transparent method for allocating access; 
 Bridging the gap between science and industry; 
 Disseminating knowledge, education and training, fostering collaboration in Europe; 
 Opening to EU Member States and countries with ‘associate’ engagement with Horizon 
2020; and 
 Providing capacity building to EU Enlargement and Integration Countries. 
There are two modes of access, for relevance-driven access and market-driven access.  
1. Potential research users for relevance-driven access apply following a call for proposals. 
There is a peer-reviewed selection process, taking into account scientific implementation, 
collaboration and access to new users, strategic relevance to the JRC and strategic 
importance for Europe. Access is mainly granted to universities and research institutions, 
public institutions, and SMEs, in association with industry. Users are only charged the 
additional costs (18% overheads) (free of charge for nuclear facilities). There is open access 
to data following an embargo period (typically 18 months), extended in case open access 
jeopardizes commercial exploitation. 
2. For market-driven access, there is an agreement between the user and the JRC research 
infrastructure. Projects are selected by the JRC with an emphasis on strategic importance 
                                        
49 TUG (AT); DESY, Jül ich, KIT and TUM (DE); FORTH (EL); ICN2, PRUAB and UPV/EHU (ES); CEA, CNRS and ESRF (FR); CNR, 
Promoscience and UMIL (IT); LU (SE); UNG (SI); STFC (UK); and EPFL and PSI (CH). 
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at EU level and on the uniqueness of the JRC facilities providing access. The access mainly 
targeted at industry and private institutions, as well as to, or in partnership with research 
institutions. Users are charged the full costs (70% overheads). Data is not disseminated via 
open schemes, but it can be used by the JRC for internal purposes. 
The JRC has had for its Nanobiotechnology Lab: 22 eligible calls, 20 calls accepted, 5 completed 
projects, with 22 user institutions and 67 users. 
In 2019, there is to be a revision of the access framework to: 
 Allow the JRC to cover travel and accommodation of users accessing JRC Research 
Infrastructures, as well as to waive the additional costs of access in the relevance -driven 
mode. 
 Possibly to include users from institutions from the RTD Spreading Excellence and Widening 
Participation list of countries. 
From October 2018, there is also funding for training and capability building for H2020 associated 
countries, for people to visit the Nanobiotechnology Lab for a week with their travel and 
accommodation paid. This is for groups of users from universities, research or public institutions, or 
from SMEs, preferably with existing or under construction RIs similar to those of JRC. The Calls are 
under the JRC Enlargement and Integration Action. 
For further information, see https://ec.europa.eu/info/departments/joint-research-centre_en  
European researchers from the top laboratories are increasingly coordinating their ef forts in shared 
platforms, particularly where the activities are far enough from the market-place for competition and 
intellectual property issues to be only minor. Some take a ‘living lab’ approach - user-centred, with a 
co-creation and open access attitude, and often funded through public-private partnership (see 
boxes below). In these, both technology push and market pull are present, with (business) ideas 
being proposed by (industry) partners, then reformulated and developed based on technology and 
taking account of the market. 
Living Lab Approach: MINATEC Campus of CEA, France 
MINATEC has adopted an approach to micro- and nanotechnology research based on the triple 
helix of higher education-research-industry. Its facilities are open to partners from academia as 
well as industry, the latter ranging from international companies to start-ups. The MINATEC 
innovation campus is home to 3,000 researchers, 1,200 students, and 600 business and technology 
transfer experts on a 20-hectare state-of-the-art campus with 13,000 m² of clean room space. It 
generates up to 350 patents and 1600 scientific articles every year and its synchrotron attracts 
researchers from many disciplines and from across the world. MINATEC has led to the creation of 
start-ups in micro- and nano-technology applications in fields including optronics, biotechnology, 
circuit design, and motion sensing. Fostering start-ups is seen as an efficient way to bring science 
and technology to society and to develop new industry. MINATEC has an annual ope rating budget 
of EUR 300 million, including EUR 50 million in capital expenditure. The Campus is intentionally 
ideally located as the local economy of Grenoble-Isère, in the heart of France’s Rhône-Alpes region, 
is built around three major technology pillars: information and communication technologies, 
biotechnologies and new energy technologies. 




Living Lab Approach: Technological District DHITECH (Lecce, Italy) 
The Apulian Nanotech Ecosystem (ANE) is comprised of research and technology organisations 
(RTOs) (e.g. CNR50, University of Bari51, IIT52, ENEA53, etc.), joint-labs amongst RTOs and firms (e.g. 
STMicroelectronics, Ospedale San Raffaele), SMEs and start-ups (e.g. TCT, MASMEC, Echolight, 
Biotec).  
The Apulian District of High Technology (DHITECH) is a non-profit consortium embedding 
enterprises, universities and public and private research organisations. It acts as an Interme diary of 
Knowledge (IoK) organisation aimed at promoting and facilitating the development of ANE. It mainly 
acts through: i) training young researchers adopting a particular educational approach to stimulate 
their entrepreneurial attitude and develop their innovation mindset; ii) facilitating public-private 
collaborations between research centres – companies – financial institutions; and iii) communicating 
and disseminating the culture of Nanotechnology and innovation within schools.  
For further information, see http://www.dhitech.it/progetti 
Efforts are increasingly going into creating networks of infrastructure and hubs to support technology 
transfer and the translation of research into potential products. One such is grouped around 
nanomedicine research and the European Technology Platform for Nanomedicine (ETPN) (see box 
below).  
The key attributes of that hub, as perceived by ETPN members are: 
 A good understanding of the needs of the community; 
 The provision of holistic and complementary services to drive forward an emerging industry; 
and 
 A services portfolio that can seamlessly cover the most critical stages of development.  
Support for Translation of Nanomedicines Research at the European Technology Platform for 
Nanomedicine (ETPN)54 
The goals of the ETPN are to: 
 Create conditions for successful translation of nanomedical advances; 
 Help nanomedicine projects to develop faster;  
 Increase the effectiveness of investment in Nanomedicine; and 
 Improve the health of citizens worldwide.  
To support the translation of nanomedicines research to the market, in 2015 the ETPN encouraged 
the submission of complementary proposals under the H2020 Framework Programme, the aim 
being to help grow the emerging industrial sector in nanomedicine. The success of the applications 
resulted in the Nanomedicine Translation Hub, with five European projects aligned with the Hub 
concept: 
 ENATRANS55: to network and support SMEs in translation of nanomedicine in Europe, 
providing a one-stop-shop to interact and share information, experience and advice, also 
enabling personal contacts. Included is:  
                                        
50 Cons igl io Nazionale del le Ricerche   https ://www.cnr.i t 
51 https ://www.uniba.i t/engl ish-vers ion/univers i ty-of-bari -a ldo-moro 
52
 Is ti tuto Ita l iano di  Tecnologia   https ://www.i i t.i t 
53 Ita lian National Agency for New Technologies, Energy and Sustainable Economic Development http://www.enea.i t/en 
54 Presentation (Technology Transfer in Nanotechnology Workshop, 18-19 October 2018, CNR Nanotec, Lecce, I taly) by 
Simon Baconnier, ETPN Safety and Characterisation Working Group https://etp-nanomedicine.eu/about-etpn/working-
groups/wg-safety-and-characterization/ and EUNCL and CEA (FR)  
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o A Translation Advisory Board (nanomedTAB) with senior experienced translation 
experts to guide R&D teams (in start-ups, SMEs and research institutes) to firstly reach 
the clinical trials stage and later the market. nanomedTAB assesses the status and 
prospects of nanomedicine projects based on standardised criteria; provides feedback 
on business, strategic and technical aspects, makes recommendations to either 
continue, re-direct, re-start or discontinue projects; guides and mentors teams whose 
innovations are deemed to be more competitive to their next stage (e.g. technical 
development, funding, partnering, regulatory, manufacturing). 
 EUNCL56: the European Nanomedicine Characterisation Laboratory, providing access to 
state-of-the-art, full characterisation (using the best available standards) of nanomaterials 
intended for medical applications, developed by public labs, spin –offs and SMEs.  
 Three pilot lines for scale up of, and manufacturing services for, nanomaterials for medical 
applications:  
o NanoPilot57, to build a GMP58 pilot line for the production of polymer-based 
nanopharmaceuticals;  
o NanoFacturing59, to scale up an existing GMP pilot line to a medium-scale 
sustainable manufacturing process for solid core nanopharmaceuticals (e.g. for 
clinical programmes on antiviral dengue fever nanopharmaceuticals) and to create 
a large-scale process platform for GMP compliant industrial manufacture, available 
as a model for other European companies wishing to develop their own products; 
and  
o MACIVIVA60, an interdisciplinary consortium of established and innovative SMEs 
with scientific excellence and industrial world-leading experts with unique know-
how in virosome technology, spray and freeze drying, large scale manufacturing 
and packaging. 
The model of ETPN is ready to be replicated in other regions. The TAB is especially suited for 
regions with high proportions of early stage projects. 
For further information, see https://etp-nanomedicine.eu  
2.7    Funding for and investment in nanotechnology 
Different technologies have different inherent timescales (e.g. a 6- to 12-month timescale for the 
development of some digital technologies versus the timescale for nanotechnologies and advanced 
materials that can be greater than ten years) and nanotechnology can be highly capital intensive, 
more than, for example, ICT. Nanotechnology research and development often requires highly 
specialised equipment, making it expensive to conduct. In addition, some of the commonly used 
nanomaterials are expensive e.g. gold. There is also a high rate of ‘failure’ of nanotechnology 
development, with researchers citing low reproducibility, making the area high-cost, high risk.  
It is essential to have a continuous stream of support, whether public or private, to bring 
nanotechnology from the laboratory to the market. In development, each step costs more than the 
preceding one and the closer the technology comes to the market, the more has been invested in it 
and the higher the impact if it should then fail. There is the gap mentioned previously between the 
furthest point that a laboratory will typically go and the earliest point that a company will typically 
                                                                                                                          








intervene. Some organisations are taking action to fill that gap (see the example earlier in this report 
of the University of Manchester / Graphene Enabled Systems Ltd) and there is also action at EU level 
for nanotechnology and other future and emerging technologies under the EU FET Innovation 
Launchpad programme of Horizon 2020 (see box below). 
The FET Innovation Launchpad under Horizon 2020 
The Future and Emerging Technologies (FET) Innovation Launchpad scheme aims to turn results 
from FET-funded projects (from FP7 or Horizon 2020) into genuine societal or economic innovations. 
The funded proposals are short individual or collaborative actions focused on the non-scientific 
aspects and the early stages of an innovation idea, stemming from ongoing or recently finished FET 
projects. The projects involve a wide range of actors, mostly from universities and research 
organisations, but also SMEs and industry partners, mostly start-up/ spin-off companies.  
Nanoscience is mostly funded through public funding for the early stages of research and 
development (low TRLs and only up to TRL2 or TRL361). If academic and research institutions bring 
research to TRL3 only, the incentive for industry to engage in the next stages – technology validation 
in the lab and in an actual environment – is low. Institutions could usefully demonstrate the potential 
of the technology in the real world by carrying it further along the development process, thereby 
making it more attractive to potential investors.  
Nanotechnology is a key enabling technology (KET) and, as such, it can be seen as being a bridge 
between research and applications, between lower and higher TRLs. The figure62 below shows the 
various stages of development grouped into three, with technology readiness levels (TRLs) and 
investor types (public, private). The Valley of Death (the point of no return after which many new 
ideas going through the innovation process fail to progress63) occurs between TRL levels 4 and 7.  
Figure 2: The development of technology, from basic principles (TRL1) to commercial market (TRL8-9) 
(From uk-cpi.com, “The Innovation Challenge and the Valley of Death” May 2016) 64 
 
                                        
61 http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2016-2017/annexes/h2020-wp1617-annex-
ga_en.pdf Technology Readiness Levels:  1 - basic principles; 2 - technology concepts; 3 - experimental proof of 
concept; 4 - technology va lidation in lab; 5 - technology va lidated in real environment; 6 – technology demonstrated in 
rea l  environment; 7 – prototype demonstration in operational environment; 8 – system complete and qualified; and 9 
– actual system proven in operational environment. 
62 Source: uk-cpi.com 
63 https ://www.uk-cpi.com/blog/the-innovation-challenge-and-the-valley-of-death 
64 Adapted from uk-cpi.com, “The Innovation Challenge and the Valley of Death” May 2016 
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From an industry perspective, grant funding for further development of/beyond research often 
requires matching funding. This is difficult for companies in an area as uncertain as nanotechnology, 
particularly for SMEs, even for small sums. Money from institutions or government funding could 
bridge the gap to help bring technologies closer to transfer and commercialisation. While the aim of 
grants with matching funding is to share risk, they start at too early a TRL for nanotechnology and 
other higher risk (but potentially higher gain) technologies. Nanotechnology also attracts a low level 
of venture capital investment, particularly low in the EU, due to its aversion to risk. Overall, venture 
capital in the US is almost six times that in Europe, when the figures are normalized for GDP 65. 
Europe may also be at a competitive disadvantage in this relative to Asia, where companies (and 
venture capitalists) are less risk-averse. 
The role of nanotechnology SMEs is often limited to the initial generation or adoption of 
nanotechnology e.g. in start-ups from universities or spin-offs from larger companies, taking 
nanotechnology to the proof of concept stage (TRL3). They are much more rarely able to bring the 
nanotechnology to validation (TRL4-5) and demonstration (TRL6-7). In other areas, such as 
biotechnology, small companies can take a technology much further up the value chain, even to 
diffusion and deployment, which needs substantial capital (from the company itself or from external 
funds such as venture capital). Investors remain slow to support nanotechnology, seeing it as high -
cost, high-risk with a long-term and uncertain return on investment. 
Nanotechnology is a disruptive technology in many ways. As new developments come on stream, 
drastic changes are expected in manufacturing and these will require huge levels of investment. For 
example, electronics and ICT have reached the end of the range of Moore’s Law 66 and the potential 
of silicon-based electronics. Changing to a non-silicon-based system will require manufacturing 
facilities to be renewed. This will have a large cost associated with it but, having reached the limits of 
silicon, there is no choice. It is more widely forecast that, in the (near) future new technologies will 
be used to produce new materials, ones that can be cheaper, more effective and more 
environmentally-friendly than those currently in use. There will be need for investments in courses 
aimed at developing innovation management skills for researchers (e.g. within doctoral training) and, 
in parallel, there should be a review of the way technology-based R&D and industry are financed, to 
better accommodate the higher risks that occur at the early stages of a period of radical change.  
The COST Innovators Grant (proposal) 
The European Cooperation in Science and Technology (COST) association provides funding for the 
creation of research networks, called COST Actions. These networks offer an open space for 
collaboration among scientists across Europe (and beyond), thereby giving impetus to research 
advances and innovation. Since 1971, COST has received EU funding to support such networks 
under the various research and innovation framework programmes, such as Horizon 2020.  
COST is bottom up, so it is researchers in any field of science that, based on their own research 
interests and ideas, can apply to create a network via a proposal to a COST Open Call. It is also 
possible for them to join ongoing COST Actions, which therefore keep expanding over the funding 
period of four years. COST Actions are multi -stakeholder, often involving the private sector, 
policymakers and civil society. It complements the research and innovation funded through other 
grants.  
COST is proposing to launch a COST Innovators Grant67 under Horizon Europe (FP9) to enhance the 
pace and success of breakthrough innovations and to build bridges between the scientific research 
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 Source: Invest Europe / EDC and EVCA Eurostat (from presentation (Technology Transfer in Nanotechnology Workshop, 
18-19 October 2018, CNR Nanotec, Lecce, Italy) by Alessandro Sannino of the University of Salento, Lecce (Italy) and 
Gelesis Inc., Boston, MA (US). 
66 See, for example, https ://phys .org/news/2018-04-power-law.html   
67 https ://www.cost.eu/wp-content/uploads/2018/08/COST_StrategicPlan_WEB.pdf 
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performed in COST Actions and marketable applications. An additional budget will be allocated to 
COST Actions that demonstrate commercial/innovation potential. The funding will cover the 
activities required to turn the research network outputs into either a commercial or technical 
proposition. The COST Innovators Grant will fund the networking, rather than the 
research/innovation activities themselves. In this, it ensures its complementary character in 
relation to other funding schemes, such as the ERC’s Proof of Concept grant. 
To fully benefit from the COST Innovators Grant and successfully implement it, COST Actions will 
also be able to apply for a one-year extension of their activities. The target is that at least 20 % of 
the completed Actions will be eligible for funding from the COST Innovators Grant from 2021 on.  
For further information, see www.cost.eu 
The European Investment Bank68 is channelling support for innovation and competitiveness via a 
number of schemes in cooperation with other finance organisations and national bodies, for 
example: 
 InnovFin69, an EU Finance for Innovators initiative launched by the European Commission and the 
EIB Group in the framework of Horizon 2020. This consists of tailored financial instruments and 
an advisory service, covering both direct loans from the European Investment Bank Group (EIB 
Group), guarantees to and equity investment via financial intermediaries. More than EUR 24bn of 
financing for research and innovation by companies (of all sizes) is expected between 2014 and 
2020.  
 Nationally in Italy, for example, via the ITAtech investment platform dedicated to technology 
transfer. The aim is to stimulate the Italian innovation ecosystem, facilitating access to equity 
and investments for innovation throughout the entire business life cycle, from start-up and seed 
stages to growth and expansion, and to exploit intellectual property. Launched in Decemb er 
2016 to transform research and technical-scientific innovations into new high-tech enterprises, 
ITAtech has an initial budget of EUR 200 million, in equal parts from the European Investment 
Fund (EIF)70 and Cassa Depositi e Prestiti (CDP) (CDP)71. 
In addition, there are specific national initiatives to support high-tech companies, which, although 
not targeted specifically at nanotechnology start-ups, can have a positive effect (see box below, The 
Italian Start-up Act, 2012). 
The Italian Start-up Act, 2012 
The Italian policy framework for innovative start-ups (the “Start-up Act”) was introduced in late 2012 
(Decree-law 179). It aims to create a favourable environment for small innovative start-ups through 
a number of complementary instruments, including “fast-track” and zero cost incorporation, 
simplified insolvency procedures, tax incentives for equity investments, and a public guarantee 
scheme for bank credits. “Innovative start-ups” are defined as newly-founded (less than 5 years old) 
unlisted limited companies, with an annual turnover under EUR 5 m, and a focus on technological 
innovation as indicated by one or more of: 
 Significant R&D expenditure (>15% of total annual costs)  
 A highly-qualified team (one third being PhD students or graduates or researchers and/or 
two-thirds holding a Master’s degree); 
 Intellectual property (IP) rights (being the holder, depository or licensee of a patent or 
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69 http://www.eib.org/en/products/blending/innovfin/index.htm  
70 http://www.eif.org 
71 https ://en.cdp.it 
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owner/author of registered software). 
Companies that fulfil the requirements can (self-)register as innovative start-ups at their local 
Chamber of Commerce and benefit from support measures designed to help them throughout their 
whole life-cycle (first steps, growth, maturity) and to benefit the national start-up ecosystem as a 
whole (investors, incubators, universities…) . The companies must be headquartered in Italy and have 
a mission statement explicitly related to innovation.  
A large variety of data is collected on firm participants. The Italian Chambers of Commerce, on 
behalf of the Ministry of Economic Development (MISE), maintains a registry on the participating 
start-ups and conducted a detailed survey on ex-ante firm characteristics such as funding sources 
and employment composition.  
An assessment (OECD, 2018)72 has shown that companies that benefit from the policy, compared to 
a control sample, show: 
• A 10-15% increase in turnover, value added, patent activity and investments in tangible and 
intangible assets; 
• Increased likelihood of obtaining bank loans, often at a lower interest rate;  
• A higher probability (more than double) of receiving venture capital in the first three years 
of the company; 
Overall, since the launch of the policy, the popularity of the start-up phenomenon in Italy has 
measurably increased.  
The OECD evaluation highlights that the impact of the policy on beneficiary firms has been positive 
overall, but that complementary policy actions in other areas are required in order to further realise 
the full potential of Italian innovative start-ups. 
For further information, see: mise.gov.it; startup.registroimprese.it; italiastartupvisa.mise.gov.it 
SMEs experience some specific challenges in being attractive to investors while retaining control of 
their intellectual property and their business. One example of a successful high-tech nanotechnology 
spin-out company with a focus on protecting intellectual property and supporting staff to understand 
its importance, is given in the box below (An SME view: Cellix Ltd.).  
An SME view: Cellix Ltd. 73 
Cellix is a spin-out company that originated in work from Trinity College, University of Dublin, 
Ireland. Since it began as a company in 2006, it has developed its product range, based on research 
and development, in the areas of microfluidic pumps and biochips for cell-based assays. It sells to 
companies (including Allergan, AstraZeneca, Merck, and Pfizer) and to academic institutions and 
research bodies in Europe, the US and across the globe.  
Cellix relies on know-how, copyright (software) and trade secrets as well as having a strong patent 
portfolio (six patent families with ten granted patents and 35 patent applications) across microfluidic 
pumps, biochips, cell-based assays; impedance and advanced electronics; and gene transfection 
assays / tools / techniques. Having recognised that the original research market it was targeting was 
quite niche and thus difficult to scale; Cellix re-pivoted its business, focusing on the development of 
innovative technologies, which form the foundation of its patent portfolio.   Now, Cellix's revenue 
model is based on that IP and it operates via licensing, joint ventures and original equipment 
                                        
72 https ://www.oecd-ilibrary.org/docserver/02ab0eb7-
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73 Adapted from presentation (Technology Transfer in Nanotechnology Workshop, 18-19 October 2018, CNR Nanotec, 
Lecce, Italy) by Vivienne Williams 
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manufacturer (OEM) agreements.  
Although Cellix began developing and selling tools into research laboratories, with its new business 
model, it has now diversified into food and beverages, agri -biotech and health and personalised 
medicine. Within these new fields, it is flourishing and has, amongst other things, developed a rapid 
diagnostic test for draught beer that is being tested by the top breweries worldwide (controlling 48% 
of the market) and beer-line cleaning companies. 
Cellix monitors its knowledge creation and IP and insists on patent filing, where necessary,  before 
any dissemination through workshops, conferences or other activities is allowed to take place. Cellix 
is currently developing its IP programme in-house, including ensuring that staff complete an 
invention disclosure form (IDF) and receive training in company IP requirements, structures and 
management.  
Although not yet implemented and still under review, Cellix has identified schemes used by other 
companies to incentivise their staff to be mindful of IP and to protect it:  
• EUR 100 / voucher / non-financial incentive for every new IDF filed with the technology 
transfer office; 
• EUR X for each successful Search Report (i.e. report on any documents to be taken into 
consideration in deciding whether an invention is patentable or not); and 
• EUR Y for each patent granted.   
Cellix is also very aware of the potential value of IP and is further developing its strategy on how best 
to monetise IP in different situations.  Their decision-making process is supported via market 
research (looking at the size of the market, the percentage of the market that is likely to be captured 
by the IP and whether the IP is better than what is already on the market (the unique selling point or 
USP)) and IP valuation models using costs (what has been invested so far), market (comparing with 
similar businesses/technology transactions as an upper limit to what and licensor will pay) and 
income (theoretical and based on revenue, profit and cash-flow estimates).  
For further information on Cellix, see: https://www.wearecellix.com 
2.8    Market adoption of nanotechnology 
Nanotechnology has the potential to make a significant impact in areas including health, transport, 
energy and construction74,75. It can be an industry disruptor (e.g. in lighting, with the incremental 
developments from tungsten to halogen to fluorescent lighting but then a leap forward to gallium 
nitride light-emitting diodes (GaN LEDs) and organic LEDs). This gives it the power to create huge new 
markets and to foster the development of an industry (something that is particularly being sought in 
ICT now that the Moore’s Law barrier has been reached). 
Nanotechnology has been adopted in niche areas such as cancer treatments (to help target 
treatments to the cancerous cells using nanoparticles of gold) but areas in which it could reach high 
market volumes are currently closed to it due to the inherent cautious nature of the industry. For 
example, nanomaterials are being promoted for building insulation and other areas in construction, 
However, the construction industry is slow to adopt such innovations, also because the materials 
they use need to last for decades, even centuries, the length of time that buildings are expected to 
last, a timeframe for which nanomaterials are untested. This is just one example of market 
                                        
74
 NanoData study for EC DG-Research and Innovation under Framework Service Contract NMP4-FC-2013-ND0000, 
conducted by the Joint Institute for Innovation Policy (www.jiip.eu) 
75 F. Matteucci, R. Giannantonio, F. Ca labi, A. Agostiano, G. Gigli and M. Rossi, Deployment and exploitation of 
nanotechnology nanomaterials and nanomedicine, AIP Conference Proceedings 1990, 020001 (2018); 
https ://doi.org/10.1063/1.5047755 
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reluctance to adopt nanotechnology, a challenge that impacts on the value chain right back to R&D. 
If a high-volume industry such as construction were to adopt nanotechnology, the costs of products 
(currently high) would drop due to scale and demand effects. Additional investment would be 
expected to follow, from the industry and external investors.  
Another issue for market adoption relates to standards and regulations. If a material cannot be 
proved to be ‘safe’, a potential purchaser will be reluctant (or unable) to buy it. While many 
companies are making nanomaterials, they may find them hard to sell. This is related to the need for 
definitions, standards, product data sheets and guidelines for the use of nanomaterials mentioned 
previously. 
Comparing with other high-tech areas, some studies76 show that the nanotechnology transfer model 
is very different from that involved in biotechnology evolution: while small –medium firms play a 
valuable technology-bringing role, the central function of “translating” new knowledge between 
public research and industry is carried by the larger firms, just as it was in the early stages of the 
microelectronics sector. These results suggest that specific policy initiatives to facilitate 
biotechnology technology transfer are inappropriate to boost the diffusion of nanotechnology.  
Many nanotechnology developments are too early stage for large companies. It is an uphill battle to 
interest them, although once they are convinced (perhaps by technology advocates with exciting 
demonstrators) they become evangelists themselves within their company or group. When the y 
commit to the project, they will defend it within their organisation up to the highest levels. 
Advocates therefore play an important role in ‘selling’ nanotechnology to industry.  
Companies can also work with each other to bring nanotechnology to the market as customer and 
supplier, optimising the speed to market through simplified engagement processes (see a company 
example in the box below: Beneq Oy). Matchmaking events and activi ties can be the first step to 
initiate such relationships.  
Beneq Oy, Finland77 
Beneq was established in May 2005 in Vantaa (Finland) as a management buy-out (MBO) spin-out 
from Nextrom (ex. Nokia-Maillefer). Its competence background (under Nextrom) came from the 
fibre optics industry. In 2012, Beneq acquired EL-display business (Finland) from Planar Inc. (US). The 
company employs 150 people including more than 10 PhDs, and has bases in Finland (headquarters), 
Germany, the USA and China. It has revenue of EUR 25 million, 97% outside of Finland (firstly, in 
APAC, secondly in the EU and thirdly in the US). It holds over 250 patents.  
Beneq Oy designs and manufactures coating equipment based on nanotechnology. It is a leading 
supplier of production and research equipment for thin film atomic layer deposition (ALD) and 
aerosol coatings, as well as manufacturer of the thin film electroluminescent (TFEL) displays that are 
produced in its Lumineq sub-unit.  
Beneq provides ALD development services and ALD coating services via a complete ALD service 
called “Thin as a Service”™. By working with customers it enables them to implement thin film 
coatings from coating chemistry research, through proof of concept to full -scale ALD production 
faster, more easily, with less risk and customised to their needs. To achieve this, Beneq places great 
importance on knowing its customer and their needs, co-creating and developing the product 
                                        
76 “Which model of technology transfer for nanotechnology? A comparison with biotech and microelectronics”,  Corine 
Genet, Khalid Errabi, Caroline Gauthier, Technovation, Volume 32, Issues 3–4, March–April 2012, Pages 205-215 
https ://doi.org/10.1016/j.technovation.2011.10.007  
77 Adapted from presentation (Technology Transfer in Nanotechnology Workshop, 18-19 October 2018, CNR Nanotec, 
Lecce, Italy) by Jukka Nieminen, Beneq Oy, and from the case s tudy on Beneq Oy in the NanoData study for EC DG -
Research and Innovation under Framework Service Contract NMP4-FC-2013-ND0000, conducted by the Joint Institute 
for Innovation Policy (www.jiip.eu) 
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together with the client.  
Beneq implements standard terms and conditions for the development service in preference to a 
joint development or similar agreement that could require lawyers and take more time. It has 
standard rules for foreground and background intellectual property with the client. The service 
process is streamlined, with clear responsibilities, well-documented so that the customer knows in 
advance what documents and deliverables they will receive. Beneq invoices in phases with a low 
entry level that is easy for the client to achieve. The application results are typically not patented,  
but protected as “trade secrets”. The accelerated and trust-based process works well for Beneq (as a 
service and equipment supplier) and for customers, who see a reduced ‘time -to-market’ if the 
product is successful.  
For further information, see: www.beneq.com 
Too often, researchers and small companies approach large companies with novel solutions to 
problems, but these have no value if they do not match the actual problems of the large company. 
Some large companies have taken the step of listing on thei r website the problems that they are 
trying to solve (e.g. GE Healthcare, Millipore-Sigma, ThermoFisher)78 and even problems that they 
are not trying to solve (e.g. GE Healthcare). It can be extremely time-consuming to contact all the 
companies that appear, from market research, to be relevant and it would be of significant benefit to 
smaller entities if large corporations could at least identify areas of interest on their website, if a list 
of desired technologies. 
Initiatives to help build partnerships between companies include corporate match-making days and 
business acceleration services (business match events) (e.g. under the EU H2020 SME Instrument 
Phase 3). For these, the organizer (such as the European Commission) works with large corporates to 
organize match-making days between large companies and SMEs (or even academics, depending on 
the position of the event relative to the nanotechnology value chain and the types of soluti ons that 
the large companies are looking to find). The SMEs apply to participate, ensuring that there is a 
reasonable vetting of the companies prior to them taking part in the match-making event.  
Partnerships between large companies and SMEs would help both to strengthen the SME and to 
bring the technology to the level where it has potential for the large company. Large companies can 
rapidly accelerate the time to market but many are cautious and slow to react, with short -term 
return on investment being an important consideration although this can disadvantage new 
opportunities. Partnerships between large and smaller companies need to be equal in terms of the 
value that each company places on the role and needs of the other. So far, there has been a 
reluctance to engage but this is being helped in part by partnership mechanisms including the EU 




                                        
78
 GE Healthcare:   
https ://www.gelifesciences.com/en/ee/business-partnerships/partnerships-and-licensing/in-licensing  







79 For example, see https://bbi-europe.eu/about/about-bbi  
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2.9    Perception and awareness of nanotechnology 
Nanotechnology has suffered both from over-hype and over-precaution. When it first emerged, it 
was oversold by many in order to obtain research funding. It was promoted as the solution to all 
possible challenges, from curing all cancers to meeting all our energy needs. Whil e it may at some 
point achieve these goals, the process of translating technology from the theoretical to the actual is a 
slow and arduous one and there needs to be a realistic assessment of the distance travelled (and still 
to be travelled) along the development path. The initial hype has died down, in some cases being 
replaced with disillusionment when the promises were not delivered on. Nanotechnology has now 
been somewhat overtaken by the broader notion of future, key enabling and emerging technologies.   
An accurate view is needed of the potential of nanotechnology for successful transfer to successive 
points on the value chain, coupled with an awareness of its potential risks and benefits. 
Communication is very important for nanotechnology because of its many facets. Nanomaterials can 
be used in many ways across many sectors and with many potential customers.  
Education is very important in achieving public awareness without excessive concern or fear. Some 
good practices that are currently being used and could be developed elsewhere and given support 
include: 
 Massive open online courses (MOOCs): For example, researchers at the University of Paris-
Sud, Labex NanoSaclay and the University of Paris-Saclay have put on MOOCs lasting seven 
weeks in 2017 and 2018 on “Understanding Nanosciences”. These are suitable for people 
with a technical background (such as a science diploma, BAC+2) rather than the broad 
general public.80 81 
 The Fondation de la Maison de la Chimie (Paris Chemistry Foundation) is organising 
conferences on nanotechnology for a large audience.82 Universities and research institutes 
(such as the CNRS) also organise science cafés and conferences for the general public . 
 Some governments use web-based methods, amongst the best-known being 
https://www.nano.gov from the US National Nanotechnology Initiative (NNI). This provides a 
definition of nanotechnology, explains why standards matter, identifies infrastructure and 
list laboratories, teaching resources, events, etc. Under technology transfer it states that:  
“Although federally-funded R&D yields hard-to-quantify benefits such as students 
educated, degrees conferred, companies started, patents and copyrights granted, 
developmental partnerships formed, and private sector investment inflows, there 
are many indicators of the impact of this investment. For example, there (were) 
over 1,900 U.S.-based companies conducting R&D, manufacturing, or product sales 
in nanotechnology in 2016…. NNI agencies have developed an extensive 
infrastructure of nearly 100 major interdisciplinary research and education centres 
and user facilities across the United States. This cutting-edge fabrication and 
characterisation equipment provides state-of-the-art nanoscience tools and 
expertise for research by non-profit or business organizations, whether small or 
large, for use-inspired research and some of the user facilities are available free-of-
charge for non-proprietary work if the user intends to publish the research results 




                                        
80 https ://www.class-central.com/course/france-universite-numerique-comprendre-les-nanosciences-10817 
81 https ://www.fun-mooc.fr/courses/course-v1:UPSUD+42003+session02/about 
82 https ://actions.maisondelachimie.com/colloque/chimie-nanomateriaux-et-nanotechnologies/ 
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In addition to sources of relevant and accurate information on nanotechnology, there are many poor 
and inaccurate ones83 that should be identified and discredited. Probably the best way to do this is to 
maximise the amount of good information so that the probability of hitting the bad information is 
reduced.  
In communicating nanotechnology, there is also the aspect of perception to be managed. Some see 
nanotechnology only as high potential while others only see it as high risk. The truth is probably 
somewhere in the middle as all materials carry some risk and there are many illustrations already of 
the potential of nanotechnology. In the past it has suffered on occasion from comparisons with 
GMOs and asbestos, although to date there is little (if any) evidence of any dangers of properly 
handled nanomaterials. Therefore, in technology transfer of nanotechnology, all stakeholders need 
to be well-informed (to the level they require) and the mechanisms need to be in place both to 
manage all aspects of nanotechnology, including its risks and rewards.  
Attitudes to nanotechnology generally vary according to the purpose for which it is being applied. For 
example, in health the public is much more willing to accept nanotechnology (and even for high risk 
procedures) to achieve benefits that can be life-prolonging or enhance the quality of life. If 
nanotechnology can reduce the need for unpleasant radiotherapies (or shorten the treatment time), 
it is very welcome to the patient. In contrast, for nanotechnology in food or cosmetics greater 
justification may be needed e.g. for nanotechnology in sweets. Attitudes are different again for 
electronics: critical dimensions in electronic components reach 10nm, 7nm even 5nm but who would 
reject a computer or a phone that is faster, offers more functions and has less energy consumption? 
There is ‘Nano inside’ and it is widely (almost unanimously) accepted. Thus, all ‘nano’ are not equal – 
or are not regarded as being equal. Indeed, reducing to the nanoscale may enable a significant 
reduction in the use of materials or may provide a substitute material to help against the existence of 
‘conflict minerals’ (e.g. tin, tungsten, gold and tantalum) that are mined in conflict zones  and can 
fund the conflict.  
Perceptions of nanotechnology can also be helped by better understanding and communication, the 
first step in that often being achieving a shared language. Engagement of human and social sciences 
in projects in disruptive technologies can provide a tool for communication of nanotechnology with 













                                        
83 For example, an Indian “Nanotech Industry” found on 
http://apctt.org/nanotech/sites/all/themes/nanotech/pdf/transfer%20of%20nanotechnologies.pdf   
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3    CONCLUSIONS FOR POLICY 
Policies for technology transfer need to be long-term and consistent, particularly for high-tech, high-
risk areas with a long time to fruition, such as nanotechnology. It is impossible to have a blanket 
approach to the development of a "best-practices" menu. Indeed, each innovation eco-system has its 
own peculiarities, which should be understood and correctly addressed through a customised 
technology transfer approach. 
Policies should include actions for both the short term (for nanotechnology ideas that are close to 
the market and need a final push) and the long term (for high potential applications that are just 
appearing on the technology horizon).  
The benefits of successful technology transfer are clear – economic and societal – making it a priority 
for policy-makers in Europe and EU Member States to address gaps, mismatches, barriers and system 
failures. They should address blockages and support technology transfer on both the supply and the 
demand side.  
Policy should foster knowledge development and transfer, strengthen the links between science and 
industry and between small and large industries in nanotechnology, and ensure clarity in standards, 
regulations and guidance for nanotechnology and nanomaterials and their uses.  
Policy actions to support nanotechnology transfer have been identified in this context, including:  
1. Acting now to achieve a standardised and accepted definition of nanotechnology that can be 
used throughout the EU (at least) and recognised globally. This is essential for many areas, 
not least for standards and regulations, for safety at work and for consumers, but also to 
enable manufacturers to produce and sell nanomaterials and nanotechnology-based 
products. 
2. Using standards to both stimulate the growth of nanotechnology markets and ensure the 
quality of European products and products fabricated in the EU, thereby also protecting the 
EU nanotechnology market from sub-standard imports. 
3. Providing long-term support for nanotechnology research when applicable (ensuring 
continuation of research beyond the lifetime of individual projects) both via Horizon 2020 
and national/regional funding. 
4. Supporting the whole value chain of nanotechnology through public or private funds, 
identifying the gaps where public funds are needed, and especially financing the most 
promising and highest potential innovations to enable them to achieve demonstration, pilot 
production, scale-up and full-scale deployment, surviving the Valley of Death. In conjunction, 
accepting that return on investment requires patience and long-term investment in 
nanotechnology, requiring rethinking of established research, investment and business 
models.  
5. Exchanging and fostering good practice in nanotechnology transfer - customising it where 
necessary - for example, drawing on models of education that foster entrepreneurs; and 
models of collaboration based on co-creation, with a mixture of technology and industry 
people working together to bring nanotechnology to market relevance, particularly important 
given the transversal nature of nanotechnology.  
6. Accepting reasonable failure without excessive penalty in all parts of the nanotechnology 
value chain but especially for nascent business ideas and entrepreneurs, and promoting 
actions that can support change of mindset.  
7. Enabling the movement of academics out to industry (e.g. creating a start-up or being 
employed in a company) but ensuring that they have a normal route of return, whether that 
venture into business works out or not. This is very important in areas such as 
nanotechnology where good ideas currently have a high rate of failure.  
8. Supporting (and using as role models for others) hubs for nanotechnology that demonstrate 
their good understanding of the needs of the community; that provide holistic and 
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complementary services to drive forward an emerging industry; and that offer a services 
portfolio that can seamlessly cover the most critical stages of development. 
9. Drawing on existing structures and networks (e.g. platforms, pilot lines, test beds) to further
support nanotechnology-related entrepreneurship through enhanced measures for
networking, mentoring and skills development (technical and non-technical skills).
10. Scanning the horizon for high-potential innovations in nanotechnology, at EU level (e.g. the
ICT Innovation Radar), nationally and at research organisations (with research/innovation
managers having a good overview of projects so that they can identify those most likely to
succeed , for prioritisation of resources and to enable dedicated technology transfer offices to
help researchers achieve realistic expectations for their work) and identifying potential
entrepreneurs who need support to bring their ideas forward.
11. Broadening the training and education in universities and other academic institutions to
include entrepreneurship and innovation management skills while also seeking to attract
those with commercial as well as technological expertise  into roles as technology transfer
managers and patent lawyers, where complementary technology and business skills are
needed.
12. Foster the understanding by academic researchers of intellectual property through a short
period of training (“nano-IP 101”) in patents, copyright, trade secrets and trademarks,
licensing and nanotechnology transfer at the start of their research careers.
13. Developing and maintaining infrastructure for nanotechnology that appropriately takes into
consideration both technology push and market pull aspects and user needs, the purpose of
the infrastructure and user needs. Through collaborative efforts and exchanges at EU level
(such as ESFRI), duplication of facilities and effort can best be avoided, and the use of facilities
optimised through exchange of best practice. Optimal use of publicly-funded
nanotechnology-related infrastructure for public good may require a review of State-aid rules 
affecting industry use of facilities and consideration of exceptions. Continue and grow the
appropriate use of EU-funded facilities for nanotechnology, such as those of the Joint
Research Centre.
14. Acknowledging the importance of the role of pilot plants and demonstrators as paths bring
research across the Valley of Death towards marketability, particularly in challenging areas
such as nanotechnology, to support such facilities and their use, linking such facilities where
appropriate and increasing good practice activities in awareness and interactions between
stakeholders.
15. Supporting nanosafety and risk research, including encouraging better (interdisciplinary)
communication between material science and risk research. This includes defining protocols
that are representative of real situations (in vivo or in vitro, with real water as opposed to
sterile laboratory water) and protocols of measurements and standards for equipment.
16. Encouraging the translation of nanosafety research into regulatory tools via EU and
international cooperation.
17. Thinking “safe by design” whenever appropriate, in preference to a subsequent need for
remediation of a problem engendered by new products or new nanotechnologies.
18. Encouraging and enabling partnerships between large companies and SMEs, to strengthen
the SME and develop the nanotechnology so it has potential for the large company.
19. Helping nanotechnology start-ups to find customers in order to maintain their presence as an
important part of the European ecosystem, e.g. by bringing start-ups to international fairs
under a “big company umbrella” and encouraging larger companies to grow their relationship
with SMEs in support of a stronger EU nanotechnology transfer environment.
20. Providing balanced and accurate information on nanotechnology for all stakeholders
according to their needs, ranging from product data sheets and handl ing advice for
manufacturers to nanotechnology MOOCs.
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21. Enhancing communication between nanotechnology stakeholders, increasing awareness and 
promote links between providers, funders, financiers, users (for a process or product) and 
consumers of nanotechnology. 
22. Becoming better at publicising the strengths of the EU in nanotechnology, as one means of 
enhancing technology transfer. This would mirror the behaviour of other countries and it 
would enable the EU to retain a more complete history of nanotechnology advances and 
actions despite changes in administration, thereby facilitating learning from past 
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Best practices  
Alessandro Sannino, Chief Project Scientist, Gelesis 
Andrew Wilkinson, CEO, Graphene Enabled 
Vivienne Williams, Chief Executive Officer, Cellix 
Assaf Anderson, Co-Founder, Materials.Zone 
Round table: Challenges, barriers and opportunities  
Alessio Beverina, Founder and Managing Partner, PANAKÈS  
Heber Verri, CEO & Cofounder, PhD TT - Technological Transfer Director, Pairstech Capital 
Management Llp UK  
Jean Charles Guibert, Senior advisor to the CEO for innovation, CEA  
Matthias Keckl, Project manager, Fraunhofer Venture Lab  
Katrien Meuwis, Senior Manager IP Business & Intelligence, IMEC 
Friday 19 October 
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Fabio Taucer, Policy Officer, Directorate-General Joint Research Centre, European Commission  
Bernd Reichert, Head of Unit, SMEs in Horizon 2020, European Agency for Small and Medium 
Enterprises  
Alessandro Apa, Senior Fund and Structuring Officer, European Investment Bank 
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Steven Tan, Director, Nascent Ventures 
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From 10:30 to 12:00 
Session rapporteur: Mattias Dinnetz, Innovation and Technology Transfer Officer, Directorate-General 
Joint Research Centre, European Commission  
Best practices  
Daniela Sottocornola, CEO, BIOTEC  
Anurag Bansal, Global Business Development Manager, Acciona R&D 
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